NovavaxNVAX
NVAX
0
Funds holding %
of 7,398 funds
–
Analysts bullish %
Fund manager confidence
Based on 2024 Q4 regulatory filings by fund managers ($100M+ AUM)
50% more funds holding in top 10
Funds holding in top 10: 2 [Q3] → 3 (+1) [Q4]
44% more repeat investments, than reductions
Existing positions increased: 78 | Existing positions reduced: 54
5.45% more ownership
Funds ownership: 58.6% [Q3] → 64.05% (+5.45%) [Q4]
5% less first-time investments, than exits
New positions opened: 39 | Existing positions closed: 41
3% less funds holding
Funds holding: 233 [Q3] → 226 (-7) [Q4]
29% less call options, than puts
Call options by funds: $65.9M | Put options by funds: $92.9M
30% less capital invested
Capital invested by funds: $1.19B [Q3] → $826M (-$361M) [Q4]
Research analyst outlook
We haven’t received any recent analyst ratings for NVAX.
Financial journalist opinion
Based on 16 articles about NVAX published over the past 30 days
Negative
Zacks Investment Research
6 hours ago
Biotech Stocks Fall After Top FDA Official Quits Over Clash With RFK Jr.
The decline in biotech stocks comes after FDA official Peter Marks' resignation, citing irreconcilable differences with the new HHS Secretary.
Negative
CNBC Television
20 hours ago
Vaccine stocks fall following FDA resignation
Dr. Kavita Patel joins 'Fast Money' to talk the impact of FDA and HHS changes on vaccines, public health policy, and more.
Negative
Fast Company
1 day ago
Vaccine stocks tumble: Moderna, Novavax, Pfizer fall after top FDA official resigns over RFK Jr. anti-vax views
Stocks of major vaccine makers dropped on Monday after the Food and Drug Administration's (FDA) top vaccine official Dr. Peter Marks resigned, citing conflicts with Health and Human Services (HHS) Secretary Robert F. Kennedy (RFK) Jr. over his views on immunization.
Negative
New York Post
1 day ago
Drug stocks sink as FDA's top vaccine official is ousted in Trump overhaul
Shares of U.S. drugmakers fell on Monday after reports that the Food and Drug Administration's top vaccine official was forced to resign, the most high-profile exit at the regulator as the Trump administration undertakes an overhaul of federal health agencies.
Negative
CNBC
1 day ago
Vaccine stocks fall after key FDA official resigns in protest of RFK Jr.
Shares of vaccine makers Moderna and Novavax, along with a range of other biotech companies, fell after the resignation of key FDA official Peter Marks. Marks stepped down in protest of Health and Human Services Secretary Robert F.
Positive
Zacks Investment Research
1 day ago
Novavax, Inc. (NVAX) Is a Trending Stock: Facts to Know Before Betting on It
Recently, Zacks.com users have been paying close attention to Novavax (NVAX). This makes it worthwhile to examine what the stock has in store.
Negative
Investors Business Daily
1 day ago
Moderna, Vaxcyte, Novavax Hammered After Key FDA Official Peter Marks Resigns
Biotech stocks were hammered Monday after Peter Marks, a top FDA official, resigned amid a clash with Robert F. Kennedy Jr. The post Moderna, Vaxcyte, Novavax Hammered After Key FDA Official Peter Marks Resigns appeared first on Investor's Business Daily.
Negative
Reuters
1 day ago
Biotech stocks tumble on reports FDA's top vaccine regulator to leave
Shares of U.S. biotech companies fell as much as 10% premarket on Monday following reports that a top vaccine official at the U.S. Food and Drug Administration had resigned, fanning worries over slower reviews for breakthrough treatments.
Neutral
Zacks Investment Research
4 days ago
Why Novavax (NVAX) Dipped More Than Broader Market Today
Novavax (NVAX) closed at $7.26 in the latest trading session, marking a -1.76% move from the prior day.
Neutral
Zacks Investment Research
1 week ago
Novavax (NVAX) Stock Dips While Market Gains: Key Facts
In the closing of the recent trading day, Novavax (NVAX) stood at $7.91, denoting a -0.57% change from the preceding trading day.
Charts implemented using Lightweight Charts™